E2F1 drives chemotherapeutic drug resistance via ABCG2

Oncogene

Volumn 33, Issue 32, 2014, Pages 4164-4172

  Rosenfeldt, M T ^a   Bell, L A ^a   Long, J S ^a   O'Prey, J ^a   Nixon, C ^a   Roberts, F ^b   Dufes C ^c   Ryan, K M ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

ABCG2; cancer; drug sensitivity; E2F1; multidrug transporters

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84905822307     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.470     Document Type: Article

References (27)

1. Polager S, Ginsberg D. E2F-at the crossroads of life and death. Trends Cell Biol 2008; 18: 528-535.
2. Iaquinta PJ, Lees JA. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007; 19: 649-657. (Pubitemid 350216426)
3. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18: 753-761. (Pubitemid 28063408)
4. Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005; 24: 2810-2826. (Pubitemid 40638092)
5. Polager S, Ofir M, Ginsberg D. E2F1 regulates autophagy and the transcription of autophagy genes. Oncogene 2008; 27: 4860-4864.
6. Wu Z, Zheng S, Yu Q. The E2F family and the role of E2F1 in apoptosis. Int J Biochem Cell Biol 2009; 41: 2389-2397.
7. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9: 785-797.
8. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58. (Pubitemid 37328807)
9. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M et al. ABCG2: a perspective. Adv Drug Deliv Rev 2009; 61: 3-13.
10. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 2012; 83: 1084-1103.
11. Bell LA, O'Prey J, Ryan KM. DNA-binding independent cell death from a minimal proapoptotic region of E2F-1. Oncogene 2006; 25: 5656-5663. (Pubitemid 44387621)
12. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 2001; 1520: 234-241. (Pubitemid 32868794)
13. Zhang Y, Bressler JP, Neal J, Lal B, Bhang HE, Laterra J et al. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res 2007; 67: 9389-9397. (Pubitemid 47535929)
14. Zhang Y, Byun Y, Ren YR, Liu JO, Laterra J, Pomper MG. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay. Cancer Res 2009; 69: 5867-5875.
15. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002; 1: 417-425.
16. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D et al. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 2002; 198: 142-156. (Pubitemid 35243872)
17. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in nonsmall cell and small cell lung cancer. Crit Rev Oncol Hematol 2010; 75: 173-234.
18. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 2004; 64: 1242-1246. (Pubitemid 38235589)
19. Bui-Xuan NH, Tang PM, Wong CK, Fung KP. Photo-activated pheophorbide-a, an active component of Scutellaria barbata, enhances apoptosis via the suppression of ERK-mediated autophagy in the estrogen receptor-negative human breast adenocarcinoma cells MDA-MB-231. J Ethnopharmacol 2010; 131: 95-103.
20. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001; 20: 1678-1687. (Pubitemid 32368015)
21. Engelmann D, Putzer BM. The dark side of E2F1: in transit beyond apoptosis. Cancer Res 2012; 72: 571-575.
22. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M et al. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012; 11: 3067-3078.
23. Helgason GV, O'Prey J, Ryan KM. Oncogene-induced sensitization to chemotherapy-induced death requires induction as well as deregulation of E2F1. Cancer Res 2010; 70: 4074-4080.
24. Zhang W, Li J, Allen SM, Weiskircher EA, Huang Y, George RA et al. Silencing the breast cancer resistance protein expression and function in caco-2 cells using lentiviral vector-based short hairpin RNA. Drug Metab Dispos 2009; 37: 737-744.
25. Bell HS, Dufes C, O'Prey J, Crighton D, Bergamaschi D, Lu X et al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest 2007; 117: 1008-1018. (Pubitemid 46556757)
26. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T et al. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 2001; 1512: 171-182. (Pubitemid 32530764)
27. Diestra JE, Scheffer GL, Catala I, Maliepaard M, Schellens JH, Scheper RJ et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002; 198: 213-219. (Pubitemid 35243879)